Ellie Allman

Ellie Allman

Auto-generated profile, based on publicly available information

Ellie Allman

Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JMJoel Manyahi
Joel Manyahi
SMSabrina J. Moyo
Sabrina J. Moyo
UKUpendo Ozeniel Kibwana
Upendo Ozeniel Kibwana
RGRichard N. Goodman
Richard N. Goodman
EAEllie Allman
Ellie Allman
ARAdam P. Roberts
Adam P. Roberts
Introduction. Carbapenem-resistant members of the family Enterobacteriaceae are emerging as a global public-health threat and cause substantial challenges in clinical practice. Gap Statement. There is a need for increased and continued genomic surveillance of antimicrobial resistance genes globally in order to detect outbreaks and dissemination of clinically important resistance genes and their associated mobile genetic elements in human pathogens. Aim. To describe the resistance mechanisms of carbapenem-resistant Escherichia coli . Methods. Rectal swabs from neonates and newly diagnosed human immunodeficiency virus (HIV) infected adults were collected between April 2017 and May 2018 and screened for faecal carriage of carbapenamases and OXA-48 producing members of the family Enterobacteriaceae. Bacterial isolates were identified using matrix assisted laser desorption ionization time of flight mass spectrometry. Antimicrobial susceptibility testing was performed by E-test. Whole genomes of carbapenem-resistant E. coli were investigated using a hybrid assembly of Illumina and Oxford Nanopore Technologies sequencing reads. Results. Three carbapenem-resistant E. coli were detected, two from neonates and one from an HIV infected adult. All three isolates carried bla NDM-5. Two E. coli from neonates belonged to ST167 and bla NDM-5 co-existed with bla CTX-M-15 and bla OXA-01, and all were carried on IncFIA type plasmids. The E. coli from the HIV infected adult belonged to ST2083, and carried bla NDM-5 on an IncX3 type plasmid and bla CMY-42 on an IncI type plasmid. All bla NDM-5 carrying plasmids contained conjugation related genes. In addition, E. coli from the HIV infected adult carried three more plasmid types; IncFIA, IncFIB and Col(BS512). One E. coli from a neonate also carried one extra plasmid Col(BS512). All three E. coli harboured resistance genes to fluoroquinolone, aminoglycosides, sulfamethoxazole, trimethoprim, macrolides and tetracycline, carried on the IncFIA type plasmid. Furthermore, E. coli from the neonates carried a chloramphenicol resistance gene (catB3), also on the IncFIA plasmid. All three isolates were susceptible to colistin. Conclusion. This is the first report, to our knowledge, from Tanzania detecting bla NDM-5 producing E. coli. The carbapenemase gene was carried on an IncFIA and IncX3 type plasmids. Our findings highlight the urgent need for a robust antimicrobial resistance (AMR) surveillance system to monitor and rapidly report on the incidence and spread of emerging resistant bacteria in Tanzania.

12 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AKAlexander D. H. Kingdon
Alexander D. H. Kingdon
EAEllie Allman
Ellie Allman
ABAnya Breen
Anya Breen
KDKara D’aRcy
Kara D’aRcy
CMClaudia McKeown
Claudia McKeown
ARAdam P. Roberts
Adam P. Roberts
Introduction: Antimicrobial resistance has existed in the environment long before its rapid emergence and detection in clinically relevant pathogens. Studying the resistance of environmental bacterial strains may allow novel resistance mechanisms to be identified before they appear in pathogenic strains. Gap Statement: Searching for antimicrobial resistance genes in environmental bacteria represents an understudied research area compared to resistance within clinically relevant pathogens. Aim: To evaluate resistance genes present within environmental non-aeruginosa Pseudomonas spp. isolates. Methodology: We screened a set of bacterial isolates from untreated wastewater from Liverpool, UK, for the presence of extended spectrum β-lactamases and carbapenemases. A sub-set of three resistant Pseudomonas spp. isolates were selected for whole-genome sequencing. We performed minimum inhibitory concentration assays against several β-lactams, and ectopic expression of four novel resistance genes within Escherichia coli . Results: Here, we report the discovery of novel class C β-lactamase genes bla PFL7 , bla PFL8 and bla PFL9 , as well as a novel subclass B2 metallo-β-lactamase bla PFM5 present within these strains. The class C genes encoded proteins with between 61-71% amino acid identity to the closest known match, bla PFL-1 . These novel β-lactamases degraded the cephalosporin nitrocefin and confer piperacillin and ceftazidime resistance to susceptible Escherichia coli when ectopically expressed. The β-lactamase inhibitor tazobactam was effective at inhibiting these enzymes. The sub-class B2 metallo-β-lactamase had 88% amino acid identity to its closet match bla PFM-1 and conferred carbapenem resistance to susceptible E. coli . The β-lactamase inhibitors relebactam, vaborbactam, xeruborbactam and captopril had no impact on the carbapenem resistance phenotype. Analogues of all these novel genes (>95% nucleotide sequence identity) were identified within publicly available whole-genome sequencing data, suggesting they are found sporadically. Conclusion: Our analysis adds to the growing number of β-lactamase genes found from environmental Pseudomonas spp. and suggests that continued surveillance of this environmental reservoir for novel, clinically relevant, β-lactamase genes is warranted.

1 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAmy McLeman
Amy McLeman
AKAlexander D. H. Kingdon
Alexander D. H. Kingdon
Robin HoevenRobin Hoeven
Robin Hoeven
GTGeorge Taylor
George Taylor
EAEllie Allman
Ellie Allman
ARAdam P. Roberts
Adam P. Roberts
We report the isolation and identification of a Paenibacillus polymyxa strain from the citizen science project; Swab and Send. Through whole genome sequencing we are able to describe the biosynthetic gene cluster of polymyxin A produced by P. polymyxa 1G (NCBI accession no. JBVPZV000000000), compare the pmxA, pmxB and pmxE genes to five other polymyxin genes encoding known polymyxin variants, and provide mass spectrometry data that supports the production of polymyxin A 1 (1157 m/z) and A 2 (1143 m/z). Polymyxins are ranked in the highest priority critically important antimicrobials classification by the WHO and are of particular importance for treating gram-negative multidrug resistant pathogens. Due to the discovery of polymyxins occurring in the 1940’s, there is little genetic research around polymyxins, and the literature focusses primarily on clinically used polymyxin E (colistin) and polymyxin B. Previous literature suggests that polymyxin A 1 has similar/lower toxicity to clinically used polymyxins E and B. To test if polymyxin A was able to overcome current resistance mechanisms to clinically used polymyxins, the cell free supernatant from P. polymyxa 1G was tested against a panel of clinical isolates with various resistance genes. We found that resistance genes mcr-1 and mcr-4 confer resistance to polymyxin A produced by our isolate meaning that, while polymyxin A has good antimicrobial activity, clinical resistance mechanisms already confer resistance to this variant of polymyxin.

1 September 2026 in Access Microbiology
Verified
Journal Article
Open access
PSPriyanka Sharma
Priyanka Sharma
AKAlexander D. H. Kingdon
Alexander D. H. Kingdon
JBJack K. Bradley
Jack K. Bradley
EAEllie Allman
Ellie Allman
SASong Ang
Song Ang
ARAdam P. Roberts
Adam P. Roberts
Candida species have been attributed to causing ~647,000 deaths annually. Candida albicans has been identified by the WHO as a priority pathogen for targeted antifungal drug development. To this end, we have screened microbial strains from the public outreach project Swab and Send for anti- Candida activity. This process identified Pseudomonas sp. SS1954.14, which displayed potent activity against C. albicans , both on agar and in a cell-free supernatant assay. Whole-genome sequence analysis identified this strain as Pseudomonas monsensis . It contains several biosynthetic gene clusters, suggesting that it can produce hydrogen cyanide, lokisin, pyoverdine and colicin/carocin, which may contribute to the observed antifungal activity. However, an active compound was separated by preparative high-performance liquid chromatography and identified through high-resolution mass spectrometry as maculosin [cyclo(Pro-Tyr)]. This cyclic dipeptide has previously been found to possess antifungal activity, but the exact biosynthetic mechanism remains undetermined. Reporting this genome alongside the associated evidence of maculosin production represents a valuable resource for biosynthetic investigations.

30 April 2026
Verified
Preprint
Open access
PSPriyanka Sharma
Priyanka Sharma
AKAlexander D. H. Kingdon
Alexander D. H. Kingdon
JBJack K. Bradley
Jack K. Bradley
EAEllie Allman
Ellie Allman
SASong Ang
Song Ang
ARAdam P. Roberts
Adam P. Roberts
Candida albicans, responsible for approximately 647,000 deaths annually, has been identified by the WHO as a priority pathogen for targeted antifungal drug development. To this end, we have screened microbial strains from the public outreach Swab and Send project for anti-Candida activity. This process identified Pseudomonas sp. SS1954.14 which displayed potent activity against Candida albicans, both on-agar and in a cell free supernatant assay. Whole-genome analysis identified this strain as Pseudomonas monsensis. It contains several biosynthetic gene clusters suggesting it can produce hydrogen cyanide, lokisin, pyoverdine, and colicin/carocin, which may contribute to the observed antifungal activity. However, an active compound was purified by preparative high-performance liquid chromatography and identified through high-resolution mass spectrometry as maculosin (cyclo-(L-Pro-L-Tyr)). This cyclic dipeptide has previously been found to possess antifungal activity, but the exact biosynthetic mechanism remains undetermined. Reporting this genome alongside the associated evidence of maculosin production represents a valuable resource for biosynthetic investigations.

7 August 2026
Verified
Preprint
Open access
PSPriyanka Sharma
Priyanka Sharma
AKAlexander D. H. Kingdon
Alexander D. H. Kingdon
JBJack K. Bradley
Jack K. Bradley
EAEllie Allman
Ellie Allman
SASong Ang
Song Ang
ARAdam P. Roberts
Adam P. Roberts
Candida albicans, responsible for approximately 647,000 deaths annually, has been identified by the WHO as a priority pathogen for targeted antifungal drug development. To this end, we have screened microbial strains from the public outreach Swab and Send project for anti-Candida activity. This process identified Pseudomonas sp. SS1954.14 which displayed potent activity against Candida albicans, both on-agar and in a cell free supernatant assay. Whole-genome analysis identified this strain as Pseudomonas monsensis. It contains several biosynthetic gene clusters suggesting it can produce hydrogen cyanide, lokisin, pyoverdine, and colicin/carocin, which may contribute to the observed antifungal activity. However, an active compound was purified by preparative high-performance liquid chromatography and identified through high-resolution mass spectrometry as maculosin (cyclo-(L-Pro-L-Tyr)). This cyclic dipeptide has previously been found to possess antifungal activity, but the exact biosynthetic mechanism remains undetermined. Reporting this genome alongside the associated evidence of maculosin production represents a valuable resource for biosynthetic investigations.